These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 151576)

  • 1. Polymorphism of carbon oxidation of drugs and clinical implications.
    Sloan TP; Mahgoub A; Lancaster R; Idle JR; Smith RL
    Br Med J; 1978 Sep; 2(6138):655-7. PubMed ID: 151576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.
    Veronese ME; McLean S
    Eur J Clin Pharmacol; 1991; 40(6):547-52. PubMed ID: 1884734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition.
    Devonshire HW; Kong I; Cooper M; Sloan TP; Idle JR; Smith RL
    Br J Clin Pharmacol; 1983 Aug; 16(2):157-66. PubMed ID: 6615690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal modelling of human polymorphic drug oxidation--the metabolism of debrisoquine and phenacetin in rat inbred strains.
    Al-Dabbagh SG; Idle JR; Smith RL
    J Pharm Pharmacol; 1981 Mar; 33(3):161-4. PubMed ID: 6116757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically determined defcts of oxidation at carbon centres of drugs.
    Smith RL; Idle JR; Mahgoub AA; Sloan TP; Lancaster R
    Lancet; 1978 Apr; 1(8070):943-4. PubMed ID: 76883
    [No Abstract]   [Full Text] [Related]  

  • 6. Polymorphic drug oxidation in humans.
    Eichelbaum M
    Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine.
    Oram M; Wilson K; Burnett D; Al-Dabbagh SG; Idle JR; Smith RL
    Eur J Clin Pharmacol; 1982; 23(2):147-50. PubMed ID: 7140803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
    Broly F; Vandamme N; Libersa C; Lhermitte M
    Br J Clin Pharmacol; 1991 Oct; 32(4):459-66. PubMed ID: 1958440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.
    Idle JR; Smith RL
    Drug Metab Rev; 1979; 9(2):301-17. PubMed ID: 158499
    [No Abstract]   [Full Text] [Related]  

  • 10. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
    Lennard MS; Tucker GT; Woods HF
    Clin Pharmacokinet; 1986; 11(1):1-17. PubMed ID: 2868819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine.
    Pierce DM; Smith SE; Franklin RA
    Eur J Clin Pharmacol; 1987; 33(1):59-65. PubMed ID: 3691597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.
    Peart GF; Boutagy J; Shenfield GM
    Eur J Clin Pharmacol; 1987; 33(4):397-402. PubMed ID: 3443146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.
    Dahl-Puustinen ML; Alm C; Bertilsson L; Christenson I; Ostman J; Thunberg E; Wikström I
    Br J Clin Pharmacol; 1990 Sep; 30(3):476-80. PubMed ID: 2121211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.
    Evans DA; Mahgoub A; Sloan TP; Idle JR; Smith RL
    J Med Genet; 1980 Apr; 17(2):102-5. PubMed ID: 7381862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms.
    Dahl ML; Llerena A; Bondesson U; Lindström L; Bertilsson L
    Br J Clin Pharmacol; 1994 Jan; 37(1):71-4. PubMed ID: 8148222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Genetic polymorphism of oxidative drug metabolism. Therapeutic and toxicologic implications].
    Eichelbaum M
    Internist (Berl); 1983 Mar; 24(3):117-27. PubMed ID: 6135670
    [No Abstract]   [Full Text] [Related]  

  • 17. Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.
    Herchuelz A; Gangji D; Derenne F; Jeanniot JP; Douchamps J
    Br J Clin Pharmacol; 1991 Jan; 31(1):73-6. PubMed ID: 2015173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Debrisoquine oxidation polymorphism in a Tasmanian population.
    Veronese ME; McLean S
    Eur J Clin Pharmacol; 1991; 40(5):529-32. PubMed ID: 1884730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative polymorphism of debrisoquine in Parkinson's disease.
    Benitez J; Ladero JM; Jimenez-Jimenez FJ; Martinez C; Puerto AM; Valdivielso MJ; Llerena A; Cobaleda J; Muñoz JJ
    J Neurol Neurosurg Psychiatry; 1990 Apr; 53(4):289-92. PubMed ID: 2341841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population].
    Dick B; Küpfer A; Molnàr J; Braunschweig S; Preisig R
    Schweiz Med Wochenschr; 1982 Jul; 112(30):1061-7. PubMed ID: 7123181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.